Lancet neurology
-
Comment Letter
Hypothermia in patients with brain injury: the way forward?
-
Comment Letter
Hypothermia in patients with brain injury: the way forward?
-
Randomized Controlled Trial Multicenter Study Comparative Study
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
The ADAGIO study investigated whether rasagiline has disease-modifying effects in Parkinson's disease. Rasagiline 1 mg per day, but not 2 mg per day, was shown to be efficacious in the primary analysis. Here, we report additional secondary and post-hoc analyses of the ADAGIO study. ⋯ Teva Pharmaceutical Industries and H Lundbeck A/S.
-
Multicenter Study Comparative Study
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
Imaging with amyloid-β PET can potentially aid the early and accurate diagnosis of Alzheimer's disease. Florbetaben (¹⁸F) is a promising ¹⁸F-labelled amyloid-β-targeted PET tracer in clinical development. We aimed to assess the sensitivity and specificity of florbetaben (¹⁸F) PET in discriminating between patients with probable Alzheimer's disease and elderly healthy controls. ⋯ Bayer Schering Pharma AG.
-
Comment Letter
Hypothermia in patients with brain injury: the way forward?